Astrazeneca Pharma India Ltd logo

Astrazeneca Pharma India Ltd

ASTRAZEN NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹19,178 Cr
Volatility
Moderate
P/E Ratio
112.68
EBITDA
₹291 Cr
Return on Equity
21.49%
Debt to Equity
0.13
Book Value
₹349.12
EPS
₹52.4
52W High
₹9,849.5
52W Low
₹7,551.5

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Astrazeneca Pharma India Ltd insights

40 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 51.4%

Weaknesses

1
  • Stock is trading at 21.9 times its book value

Growth Rate

Revenue Growth
31.15% ↗
Net Income Growth
62.06% ↗
Cash Flow Change
-123.16% ↘
ROE
43.08% ↗
ROCE
31.61% ↗
EBITDA Margin (Avg.)
-24.81% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk high

Astrazeneca Pharma India Ltd is a subsidiary of global pharmaceutical giant AstraZeneca, currently valued at a market cap of Rs 19,766 Cr with a PE of 116.5x. The company has delivered strong 31% TTM sales growth but profits have declined 18% TTM, while maintaining a consistent ROE of 22-23% over 3-5 years.

Bull Case 7
  • Exceptional TTM revenue growth of 31%, significantly outpacing its own 10-year compounded sales CAGR of 15%, indicating accelerating top-line momentum
  • Consistent ROE of 22-23% over 3, 5, and 10-year periods demonstrates sustained capital efficiency and quality of franchise
  • Compounded sales growth of 31% over 3 years reflects a structural step-up in the business driven by parent company's oncology and specialty pipeline
  • Healthy dividend payout ratio of 51.4% signals shareholder-friendly capital allocation and confidence in cash flow generation
  • Long-term stock price CAGR of 22% over 10 years and 26% over 3 years demonstrates sustained wealth creation track record
  • Compounded profit growth of 43% over 10 years reflects strong long-term earnings compounding despite near-term dip
  • Backed by AstraZeneca Plc globally, providing access to a robust R&D pipeline and new product launches in oncology, respiratory, and cardiovascular segments
Bear Case 8
  • PE ratio of 116.5x is extremely elevated, pricing in significant future growth and leaving minimal margin of safety for earnings misses
  • Price-to-book of 22.6x is exceptionally high, indicating the stock trades at a steep premium to tangible asset value
  • TTM profit has declined 18% even as sales grew 31%, pointing to margin compression or one-off cost escalation
  • Stock price has delivered negative 6% returns over the past 1 year, underperforming broader markets despite strong revenue growth
  • Dividend yield of only 0.46% offers minimal income cushion at current elevated valuations
  • Significant divergence between 3-year sales CAGR of 31% and 3-year profit CAGR of 15% suggests operating leverage is not translating into proportionate bottom-line growth
  • As an MNC subsidiary, strategic decisions on product launches, pricing, and capital allocation rest with the parent, limiting minority shareholder influence
  • 5-year profit CAGR of 16% versus 5-year sales CAGR of 23% indicates sustained margin dilution over a longer horizon

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 19h ago
Headwinds 3
  • NPPA ₹148.66 Cr demand notice Jul 30

    NPPA issued a ₹148.66 crore demand notice for alleged overcharging of Symbicort Turbuhaler under DPCO 2013. This is a material regulatory liability.

  • NPPA ₹80L Betaloc demand Jul 28

    Separate NPPA demand of ₹79.97 lakh for alleged overcharging of Betaloc-50 tablets in 2016. Company is reviewing the notice.

  • Net profit drops 32% in Q1 Aug 10

    Despite 30% revenue growth, net profit declined 32% YoY to ₹379.3 million in Q1FY27 due to margin compression and exceptional items.

Positives 3
  • Revenue surges 30% in Q1FY27 Aug 10

    Revenue grew 30% YoY to ₹6,828 million driven by Oncology (+26%) and Biopharmaceuticals (+36%), signalling strong demand across key therapy areas.

  • CDSCO approves Enhertu expansion Aug 8

    Received CDSCO approval to import Enhertu for additional HER2-positive breast cancer indication with residual disease, expanding oncology portfolio.

  • ₹36 per share dividend declared Aug 10

    47th AGM approved ₹36 per share dividend, reflecting confidence in cash generation despite profit headwinds.

Neutral 2
  • Investor meet scheduled Aug 19 Aug 15

    Virtual one-on-one meeting with institutional investors scheduled for August 19, 2026 under SEBI Regulation 30.

  • CFO Bhavana Agrawal resigns Jul 21

    CFO resigned effective August 31, 2026 to take a regional role within AstraZeneca Group. No successor announced yet.

TL;DR: AstraZeneca Pharma India is delivering strong top-line momentum with 30% revenue growth led by oncology and biopharma, supported by new drug approvals like Enhertu. However, profitability is under pressure with a 32% profit decline, and the ₹148.66 crore NPPA demand notice poses a material regulatory overhang. The CFO transition adds near-term uncertainty. The revenue trajectory is encouraging, but margin recovery and resolution of NPPA demands will be key to watch in coming quarters.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
295
311
306
383
388
408
440
480
526
559
612
579
683
Expenses
228
258
291
334
349
355
363
394
445
484
567
518
634
Operating Profit
67
53
15
49
38
53
77
86
81
75
45
61
49
OPM %
23%
17%
4.9%
13%
10%
13%
17%
18%
15%
13%
7%
11%
7%
Other Income
8
25
10
9
-49
8
-26
10
11
1
7
5
9
Interest
0
0
1
0
0
0
0
1
1
1
1
2
2
Depreciation
4
4
4
4
4
9
9
18
17
3
4
6
5
PBT
71
73
20
54
-15
51
42
78
75
73
47
58
51
Tax %
25%
29%
23%
27%
-22%
25%
27%
26%
25%
26%
30%
23%
25%
Net Profit
54
52
16
39
-12
38
31
58
56
54
33
45
38
EPS in Rs
21.54
20.95
6.32
15.79
-4.72
15.37
12.34
23.3
22.33
21.69
13.04
17.95
15.17
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
517
564
544
571
728
832
814
806
1,003
1,296
1,716
2,276
2,432
Expenses
528
547
506
525
657
711
678
719
838
1,111
1,462
2,014
2,202
Operating Profit
-11
16
37
46
71
121
135
86
165
184
254
262
230
OPM %
-2.2%
2.9%
7%
8%
10%
15%
17%
11%
16%
14%
15%
12%
9%
Other Income
6
7
14
12
16
13
13
15
-14
51
-56
23
21
Interest
0
0
0
0
0
1
1
1
1
1
1
4
6
Depreciation
15
17
16
15
15
19
20
17
16
15
40
29
17
PBT
-21
6
36
44
73
114
127
83
134
220
156
252
228
Tax %
0%
9%
44%
41%
25%
37%
27%
26%
26%
26%
26%
26%
—
Net Profit
-21
5
20
26
54
72
93
62
99
162
116
188
170
EPS in Rs
-8.34
2.1
8.02
10.36
21.78
28.88
37.32
24.64
39.72
64.6
46.3
75.01
67.85
Div. Payout %
0%
0%
0%
0%
0%
3%
5%
41%
40%
37%
69%
48%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5
5
5
5
5
5
5
5
5
5
5
5
Reserves
146
151
218
242
296
359
451
506
584
707
765
868
Borrowings
0
0
0
0
0
12
12
9
7
5
36
111
Other Liabilities
261
247
193
214
261
330
306
337
389
362
712
1,006
Total Liabilities
412
403
415
461
562
706
775
857
985
1,078
1,518
1,989
Fixed Assets
101
97
87
75
75
72
81
74
69
67
64
117
CWIP
12
6
5
4
7
24
4
2
1
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
298
299
324
382
480
611
690
780
915
1,011
1,454
1,872
Total Assets
412
403
415
461
562
706
775
857
985
1,078
1,518
1,989
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-46
57
38
9
55
87
105
101
58
28
65
-15
Investing
-19
-4
0
-9
4
-171
173
5
18
22
31
19
Financing
0
-1
0
0
0
-6
-9
-9
-24
-44
-66
-92
Net Cash Flow
-64
53
38
-1
59
-90
269
96
52
5
31
-88
Free Cash Flow
-69
48
33
3
37
74
99
94
53
18
64
-18
CFO/OP
393
365
133
28
126
100
101
146
60
46
51
26
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
30
54
29
35
40
37
38
39
39
43
39
34
Inventory Days
157
141
121
229
186
197
198
164
193
140
208
272
Days Payable
203
174
184
257
266
251
221
223
231
121
173
207
Cash Conversion Cycle
-16
21
-34
7
-39
-17
15
-20
1
62
74
99
Working Capital Days
-15
-28
-36
-8
-14
-16
-17
-34
-18
20
22
50
ROCE %
-13%
4%
15%
19%
27%
34%
30%
16%
31%
31%
33%
29%

Shareholding Pattern

As of Jun 2026
Promoters 75.00%
Public 13.76%
DIIs 6.08%
FIIs 2.68%
Others 2.48%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
2.69%
0.00%
2.74%
2.79%
2.90%
2.93%
2.89%
3.03%
2.74%
2.71%
2.78%
2.68%
DIIs
0.83%
0.94%
0.96%
1.00%
1.02%
1.10%
1.12%
1.44%
1.42%
1.93%
2.43%
2.75%
3.78%
5.01%
5.10%
5.22%
4.65%
4.56%
5.26%
5.56%
5.80%
6.08%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
19.53%
19.72%
19.69%
19.44%
19.06%
18.62%
18.54%
18.56%
18.46%
18.12%
17.44%
17.09%
16.33%
15.00%
14.77%
14.62%
15.16%
15.18%
14.39%
14.14%
13.88%
13.76%
Others
4.64%
4.34%
4.34%
4.57%
4.92%
5.28%
5.34%
5.01%
5.12%
4.95%
2.44%
5.15%
2.15%
2.20%
2.23%
2.24%
2.31%
2.23%
2.61%
2.59%
2.55%
2.48%
No. of Shareholders
0
63,753
68,077
66,444
62,183
57,760
53,980
49,085
42,146
38,946
32,380
29,032
29,418
27,169
27,615
27,322
32,466
34,378
32,914
31,551
29,007
29,338

Documents

Frequently Asked Questions about Astrazeneca Pharma India Ltd

What does Astrazeneca Pharma India Ltd do?
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]
Where is Astrazeneca Pharma India Ltd (ASTRAZEN) listed?
Astrazeneca Pharma India Ltd is listed on the Indian stock exchanges. It is listed on NSE: ASTRAZEN and BSE: 506820. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Astrazeneca Pharma India Ltd belong to?
Astrazeneca Pharma India Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd has a market capitalisation of approximately ₹19177.50 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Astrazeneca Pharma India Ltd?
The Price-to-Earnings (PE) ratio of Astrazeneca Pharma India Ltd is 112.68. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Astrazeneca Pharma India Ltd?
Over the past 52 weeks, Astrazeneca Pharma India Ltd has traded between a low of ₹7,551.5 and a high of ₹9,849.5. This range helps investors understand the stock's price volatility and recent trading levels.
Does Astrazeneca Pharma India Ltd pay dividends?
Yes, Astrazeneca Pharma India Ltd has a dividend yield of 0.47%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd has a Return on Equity (ROE) of 21.49%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Astrazeneca Pharma India Ltd on Tapetide?
On Tapetide, you can view Astrazeneca Pharma India Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]

Website astrazenecaindia.com
CEO Ms. Bhavana Agrawal
Employees 600
Listed 2001-05-04
Face Value ₹ 2
Issued Size 2,50,00,000

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List